Earnings Per Share
EPS (Basic)
Alnylam Pharmaceuticals EPS (Basic) increased by 37.2% to $1.55 in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1207.1%, from $-0.14 to $1.55. Over 4 years (FY 2021 to FY 2025), EPS (Basic) shows an upward trend with a -24.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementIncome Statement
SectionEarnings Per Share
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
An increase indicates improved profitability or a reduction in share count, while a decrease suggests declining earnings or equity dilution.
Detailed definition
Basic earnings per share represents the portion of a company's profit allocated to each outstanding share of common stoc...
Peer comparison
Investors compare this across large-cap technology peers to assess the efficiency of earnings generation relative to the equity base.
Metric ID:
eps_basicHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$1.61 | -$1.72 | -$2.16 | -$2.00 | -$2.29 | -$3.32 | -$1.69 | -$1.40 | -$2.21 | $1.18 | -$1.09 | -$0.52 | -$0.13 | -$0.87 | -$0.66 | -$0.14 | -$0.51 | $1.91 | $1.13 | $1.55 |
| QoQ Change | — | -6.8% | -25.6% | +7.4% | -14.5% | -45.0% | +49.1% | +17.2% | -57.9% | +153.4% | -192.4% | +52.3% | +75.0% | -569.2% | +24.1% | +78.8% | -264.3% | +474.5% | -40.8% | +37.2% |
| YoY Change | — | — | — | — | -42.2% | -93.0% | +21.8% | +30.0% | +3.5% | +135.5% | +35.5% | +62.9% | +94.1% | -173.7% | +39.4% | +73.1% | -292.3% | +319.5% | +271.2% | >999% |
Range-$3.32 – $1.91
CAGR-0.8%
Avg YoY Growth+105.8%
Median YoY Growth+37.5%
EPS (Basic) at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's eps (basic)?
- Alnylam Pharmaceuticals (ALNY) reported eps (basic) of $1.55 in Q1 2026.
- How has Alnylam Pharmaceuticals's eps (basic) changed year-over-year?
- Alnylam Pharmaceuticals's eps (basic) increased by 1207.1% year-over-year, from $-0.14 to $1.55.
- What is the long-term trend for Alnylam Pharmaceuticals's eps (basic)?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's eps (basic) has grown at a -24.1% compound annual growth rate (CAGR), from $-7.20 to $2.39.
- What does eps (basic) mean?
- The amount of profit a company makes for every single share of its common stock currently held by investors.